{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:45:55Z","timestamp":1792179955092,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["06\/2020"],"award-info":[{"award-number":["06\/2020"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004913","name":"University of Palermo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP B73C22001250006"],"award-info":[{"award-number":["CUP B73C22001250006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ymthe.2024.10.028","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:06:11Z","timestamp":1730257571000},"page":"4514-4523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression"],"prefix":"10.1016","volume":"32","author":[{"given":"Ignazio","family":"Fiduccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Zizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perriera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Melfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tutone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-8252","authenticated-orcid":false,"given":"Laura","family":"Lentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Pibiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.10.028_bib1","first-page":"326","article-title":"The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis","volume":"40","author":"Clarke","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2024.10.028_bib2","first-page":"400","article-title":"Nonsense Mutations in Eukaryotes","volume":"87","author":"Potapova","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2024.10.028_bib3","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.3390\/ijms21176420","article-title":"Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems","volume":"21","author":"Pibiri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.028_bib4","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1101\/gad.1566807","article-title":"Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function","volume":"21","author":"Isken","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2024.10.028_bib5","doi-asserted-by":"crossref","first-page":"9449","DOI":"10.3390\/ijms21249449","article-title":"Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches","volume":"21","author":"Lombardi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.028_bib6","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.028_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/brv.12657","article-title":"Deciphering the molecular mechanism of stop codon readthrough","volume":"96","author":"Palma","year":"2021","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"10.1016\/j.ymthe.2024.10.028_bib8","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1093\/nar\/13.17.6265","article-title":"Suppression of a nonsense mutation in mammalian cells in\u00a0vivo by the aminoglycoside antibiotics G-418 and paromomycin","volume":"13","author":"Burke","year":"1985","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.028_bib9","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2024.10.028_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/937861","article-title":"Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection","volume":"2011","author":"Huth","year":"2011","journal-title":"Int. J. Otolaryngol."},{"key":"10.1016\/j.ymthe.2024.10.028_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.028_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymthe.2024.10.028_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymthe.2024.10.028_bib15","first-page":"43","article-title":"Mechanism of the action of amoxanox (AA-673), an orally active antiallergic agent","volume":"78","author":"Saijo","year":"1985","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.ymthe.2024.10.028_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1745-6215-10-30","article-title":"A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial","volume":"10","author":"Meng","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.ymthe.2024.10.028_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/ijms22010344","article-title":"Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations","volume":"22","author":"McHugh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.028_bib18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.10.028_bib19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ymthe.2023.01.014","article-title":"Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis","volume":"31","author":"Leroy","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.028_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.028_bib21","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.10.028_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acsmedchemlett.9b00609","article-title":"Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs)","volume":"11","author":"Tutone","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2024.10.028_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.028_bib25","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.10.028_bib26","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.3390\/ijms24119609","article-title":"Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2\u2019-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTR","volume":"24","author":"Carollo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.028_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2015.06.038","article-title":"Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives","volume":"101","author":"Pibiri","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.10.028_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejmech.2016.06.048","article-title":"Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening","volume":"122","author":"Pibiri","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.10.028_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejmech.2018.09.057","article-title":"Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs","volume":"159","author":"Pibiri","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2024.10.028_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113886","article-title":"Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation","volume":"156","author":"Corrao","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2024.10.028_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015084","article-title":"Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression","volume":"24","author":"Perriera","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.028_bib32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/biomedicines10040886","article-title":"Novel Translational Read-through-Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome","volume":"10","author":"Bezzerri","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2024.10.028_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.576","article-title":"In\u00a0vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren","volume":"8","author":"Kong","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ymthe.2024.10.028_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199573","article-title":"A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies","volume":"13","author":"McHugh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.10.028_bib35","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.028_bib36","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/hmg\/dds223","article-title":"Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy","volume":"21","author":"Kayali","year":"2012","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:46:44Z","timestamp":1778816804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1525001624006889"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.028","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}